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Abstract
Background: Epstein-Barr virus (EBV) infection is a well characterized etiopathogenic factor for a variety of
immune-related conditions, including lymphomas, lymphoproliferative disorders and autoimmune diseases. EBV-
mediated transformation of resting B cells to proliferating lymphoblastoid cells occurs in early stages of infection
and is an excellent model for investigating the mechanisms associated with acquisition of unlimited growth.
Results: We investigated the effects of experimental EBV infection of B cells on DNA methylation profiles by using
high-throughput analysis. Remarkably, we observed hypomethylation of around 250 genes, but no hypermethylation.
Hypomethylation did not occur at repetitive sequences, consistent with the absence of genomic instability in
lymphoproliferative cells. Changes in methylation only occurred after cell divisions started, without the participation of
the active demethylation machinery, and were concomitant with acquisition by B cells of the ability to proliferate. Gene
Ontology analysis, expression profiling, and high-throughput analysis of the presence of transcription factor binding
motifs and occupancy revealed that most genes undergoing hypomethylation are active and display the presence of
NF-B p65 and other B cell-specific transcription factors. Promoter hypomethylation was associated with upregulation
of genes relevant for the phenotype of proliferating lymphoblasts. Interestingly, pharmacologically induced
demethylation increased the efficiency of transformation of resting B cells to lymphoblastoid cells, consistent with
productive cooperation between hypomethylation and lymphocyte proliferation.
Conclusions: Our data provide novel clues on the role of the B cell transcription program leading to DNA
methylation changes, which we find to be key to the EBV-associated conversion of resting B cells to proliferating
lymphoblasts.
Background
Infection of B cells with Epstein-Barr virus (EBV), which
is highly prevalent in humans, is an excellent model to
investigate the molecular mechanisms associated with
the acquisition of unlimited growth during disease.
EBV-associated changes in B cells are relevant to the
development and progression of lymphomas [1] and
lymphoproliferative disorders in immune-suppressed
individuals, and various autoimmune disorders like rheu-
matoid arthritis, systemic lupus erythematosus and mul-
tiple sclerosis [2]. In early primary human infection, EBV
infects peripheral resting B cells and expresses six nuclear
(EBNA1, 2, 3A, 3B, 3C and -LP) and two latent mem-
brane proteins and small non-coding RNAs. This type
of infection, in which these two groups of proteins
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transform resting B lymphocytes into continuously prolif-
erating lymphoblastoid cell lines, is referred to as type III
latency [1,3]. This process mimics antigen-induced clonal
expansion of resting B cells associated with MYC-
mediated proliferation and upregulation of NF-B, MAP
kinases and antiapoptotic factors. Recent data have
shown that EBNA2, which is essential to this process,
enhances and exploits the B cell transcription program
by binding to a variety of B cell transcription factor sites
to achieve transformation [4]. In vivo, the vigorous cellu-
lar immune response directed against EBV-immortalized
cells limits the proliferation and expansion of such
latently infected cells at early stages of infection of a
naïve host or in immunocompromised individuals. Study-
ing type III latency lymphoblastoid cells is relevant
because it not only allows the investigation of early steps
in infection and the effects that the viral activity exerts
on B cell function, but also is an excellent strategy for
investigating changes related to the triggering of unlim-
ited proliferation of B cells, before any additional second-
ary transforming genetic and epigenetic events occur.
The mechanisms by which B cell identity is altered in
this process towards unlimited proliferation, triggered by
EBV infection, involve the acquisition of epigenetic
changes. In this context, DNA methylation might play a
key role, since this epigenetic mark participates in regu-
lating transcriptional activity [5] and is known to be
highly aberrant in several types of EBV-associated lym-
phomas [6,7] and autoimmune diseases [8]. Despite its
role in gene control, DNA methylation is not only a
mechanism of transcriptional control but also guarantees
genomic stability. The relationship between methylation
and transcriptional activity has been best studied in pro-
moter regions, particularly CpG island-associated promo-
ters, where methylation is generally associated with
transcriptional repression. In the context of the hemato-
poietic system, DNA methylation profiling has revealed
overall higher methylation levels in the lymphoid branch
relative to the myeloid one, and with respect to less dif-
ferentiated progenitors [9].
A number of studies have addressed the analysis of
DNA methylation changes associated with EBV infection
of B cells. Several of these have revealed that whereas
the EBV genomic sequence is virtually unmethylated in
free viral particles and lymphoblastoid cells, the genome
is heavily methylated in both Burkitt and Hodgkin lym-
phomas [10]. Also, the DNA methylation status of EBV
promoters has been widely studied in association with
the activity of latency promoters [11-14]. By contrast,
fewer studies have addressed the acquisition of DNA
methylation changes by the host cell during EBV-
mediated transformation between resting B cells and
proliferating lymphoblasts. EBV influences changes in
the DNA methylation status at specific sequences
[15-17] and these are likely to influence or modify the B
cell phenotype and function. It is therefore of inherent
interest to investigate the extent and mechanisms of
acquisition of changes in DNA methylation by B cells
following EBV infection as well as their potential contri-
bution to phenotypic changes during this process.
In this study we investigated the acquisition of DNA
methylation changes during EBV-mediated transforma-
tion of resting B cells to lymphoblastoid cell lines by
using methylation bead arrays. We exclusively observed
significant hypomethylation of around 250 genes. No
hypermethylation was found. Time course analysis indi-
cated that hypomethylation occurs only when cell prolif-
eration has started, suggesting the exclusive participation
of replication-dependent mechanisms. Gene Ontology
(GO) analysis, comparison with the expression patterns
of different cell types and between resting B cells and
proliferating lymphoblasts, high-throughput analysis of
the presence of transcription factor binding motifs and
occupancy revealed that most genes undergoing hypo-
methylation are active and display the presence of NF-B
p65 and other B cell-specific transcription factors. In
addition, hypomethylation associates with upregulation
of several genes that are essential in the transformation
of resting B cells to continuously proliferating lympho-
blasts. Pharmacologically induced DNA demethylation
increases B cell transformation efficiency. Our data pro-
vide novel clues to the contribution of epigenetic
mechanisms associated with EBV-associated conversion
of resting B cells to proliferating lymphoblasts, the rele-
vance of the cell type context and why DNA hypomethy-
lation could be key in the efficiency of this process.
Results
DNA methylation profiling reveals that EBV-mediated B
cell to lymphoblastoid transformation is associated with
gene-specific hypomethylation
To investigate the acquisition of DNA methylation
changes in association with EBV-associated transformation
of resting B lymphocytes (RBLs), we first compared the
DNA methylation profiles of six samples before and after
EBV infection, once they had become lymphoblastoid cell
lines (LCLs). To this end, we used methylation bead arrays
that interrogate the DNA methylation status of over
27,000 informative CpG sites, including the region near
the transcription start sites of more than 14,000 promo-
ters. Statistical analysis of the combined data from the six
pairs of samples revealed that 256 genes were hypomethy-
lated (fold change (FC) > 2; false discovery rate (FDR)
adjusted P < 0.05, Student’s t-test) in B lymphoblastoid
cells compared with resting B cells (Figure 1a; Additional
file 1). By contrast, no hypermethylated genes were
observed under these conditions. Scatterplots comparing
the average DNA methylation patterns of the six RBLs
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GO category p-value
GO: 0006955 Immune response 8.83E-05
GO: 0007156 Homophilic cell adhesion 1.91E-04
GO: 0006959 Humoral immune response 2.25E-04
GO: 0050853 B cell receptor signaling pathway 8.82E-04
GO: 0006954 Inflammatory response 1.81E-03
GO: 0006935 Chemotaxis 2.04E-03
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Figure 1 High-throughput methylation comparison of resting B lymphocytes and matching lymphoblastoid cells. (a) Heatmaps including
the data for the six RBL/LCL pairs of samples showing significant differential methylation. The left panel shows all the genes showing a FDR < 0.05.
Only those genes with a FC > 2 were selected (right panel). Data from the Illumina array were normalized as xi = xi - row.mean[i])/(0.333 × row.sd
[i]). A scale is shown at the bottom, whereby positive (red) and negative (blue) values correspond, respectively, to higher and lower than average
methylation status. M, male; F, female. (b) Scatterplots showing methylation profiles of matching RBL/LCL pairs. Genes with significant differences
(FC > 2, FDR < 0.05) in averaged results from six samples are highlighted in red. Six panels are shown: top left, mean of six experiments/pairs of
samples; middle left, male samples; bottom left, female samples; right panels, three individual RBL/LCL comparisons. (c) Band patterning
corresponding to the analysis of unmethylated/methylated Alu (AUMA) repeats. Four RBL/LCL (M, male; F, female) pairs are shown. To illustrate the
sensitivity toward DNA methylation changes, a B cell sample is compared with the same sample following limited treatment with SssI DNA
methyltransferase. (d) Comparison of the methylation levels in RBLs and LCLs for all the CpGs represented in the 27k bead array and CpGs that
undergo hypomethylation in this process. Box and whisker plots are presented, where the bottom and top of the box are the 25th and 75th
percentile and the bar near the middle is the 50th percentile (the median). (e) Gene Ontology (GO) analysis of hypomethylated genes during
EBV-mediated RBL to LCL conversion.
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and matching LCLs had highly reproducible DNA methy-
lation profiles among different samples (Figure 1b).
Changes corresponding to the average six pairs of B cells/
lymphoblastoid cells were almost identical to the pattern
obtained for only male or only female RBL/LCL compari-
sons, or those changes obtained for each individual pair of
samples (Figure 1b), highlighting the specificity of the dif-
ferences observed.
Since disease-related hypomethylation alterations gen-
erally affect repetitive elements, we also investigated
changes in CpG sites in this type of sequence. In humans,
most of the methylated cytosines are found in CpG-rich
sequences within the tandem and interspersed repeats
that constitute up to 45% of the human genome, of
which Alu repeats are the most common family. We
used genome-wide amplification of unmethylated DNA
Alu repeats (AUMA) [18] to perform high-throughput
screening of DNA methylation at these sequences. This
experiment revealed no differences between RBLs and
LCLs, suggesting that loss of methylation does not occur
in repetitive sequences (Figure 1c).
Our analysis revealed a mean 21.5% methylation among
the 256 genes undergoing demethylation in RBLs (Figure
1d). This average level of methylation at or near promoters
is compatible with active gene expression in resting B cells.
In fact, GO analysis showed significant enrichment (P <
0.05) for the following categories assigned to biological
processes: immune response (GO:0006955; P-value = 8.8
× 10-5), humoral immune response (GO:0006959; P-value
= 2.2 × 10-4), B cell receptor signaling pathway
(GO:0050853; P-value = 8.8 × 10-4), inflammatory
response (GO:0006954; P-value = 1.8 × 10-3) and chemo-
taxis (GO:0006935; P-value = 2.0 × 10-3) (Figure 1e).
These categories include the presence of key markers of B
cell function and identity, such as CD19, CD79a and
BLNK. Among the list of hypomethylated genes, the pre-
sence of genes that are EBV-induced, such as CCR7
(EBI1), GPR183 (EBI2), EBI3 (IL27 subunit beta) and
TRAF1 (EBI6), is also noteworthy.
To confirm that differences identified in DNA methyla-
tion between B cells and B lymphoblasts were robust, we
carried out bisulfite genomic pyrosequencing of selected
genes looking at CpG sites corresponding to the oligonu-
cleotide probe represented in the methylation array, which
is generally located around the transcription start site. We
selected 20 genes on the basis of the magnitude of change
in methylation, as revealed by the analysis of our methyla-
tion arrays, and their functional relevance in the context
of B cell biology: CD19, CD79a, BLK, FCER2, LCK, BLNK,
IL21, CCL3L1, SLAMF7, IL25, IRS2, TAP1, COLEC12,
MAP3K7IP1, TCL1A, CD1C, CD80 and DOK3, including
two of the genes originally described as EBV-induced
(CCR7 and TRAF1). In all cases, bisulfite pyrosequencing
of these genes confirmed an at least two-fold significant
decrease for the aforementioned genes (Figure 2a;
Additional file 2).
Hypomethylation associated with EBV-mediated
transformation of RBLs to LCLs occurs in association with
proliferation and does not involve active demethylation
mechanisms
Our results indicated that the transformation of resting
B cells to proliferating B lymphoblastoid cells is associated
with gene promoter hypomethylation. Loss of methylation
may occur as a result of the defective maintenance of
DNA methylation as DNA replication and subsequent cell
divisions start or, alternatively, as an active mechanism. To
discriminate between these two possibilities, we first per-
formed bisulfite genomic pyrosequencing of the genes pre-
viously analyzed in samples generated over time, including
points at 1, 3 and 24 hours, before cell proliferation had
been initiated [19], and LCLs after 1 and 2 weeks. To this
end, we used a form of EBV that infects B cells very effi-
ciently [20] and in which around 90% of B cells express
EBNA2 (Figure 2b). The results showed that significant
demethylation only occurred after cell divisions have
started to take place (Figure 2c), although the coincidence
in time with replication does not necessarily mean
that hypomethylation takes place through a passive
mechanism.
A variety of factors are known to be involved in active
demethylation. Recent studies have drawn attention
towards a family of enzymes, the Tet proteins, that con-
vert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine
(5hmC) and other modified forms of cytosine. 5hmC
may represent intermediates in the process leading to
active DNA demethylation [21,22]. In addition, activa-
tion-induced deaminase (AID) participates in active
demethylation in a two-step process, whereby 5mC is
first deaminated by AID to thymine, followed by G/T
mismatch-specific thymine DNA glycosylase (TDG)-
mediated excision repair [22,23]. This process could
potentially take place on 5mC, although some studies
have shown that hydroxymethylation may target the
methylcytosine residues that are going to be demethy-
lated through this process [22]. Analysis of the 5hmC
levels at different times in several genes that become
hypomethylated during RBL to LCL transformation
showed neither a significant presence of 5hmC on the
CpGs that undergo hypomethylation nor any changes
during this process (Figure 2d). We did not see any sig-
nificant change in the expression levels of Tet proteins
(not shown) during this process. We also investigated the
potential involvement of AID in hypomethylation. AID is
overexpressed during EBV-mediated conversion of RBLs
to LCLs. RT-PCR and western blot analysis of AID
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revealed an increased expression of AID during this pro-
cess (Figure 2e). Recent ChIP-seq data have also served
to identify direct AID targets in B cells [24]. Comparison
of these data with our own hypomethylation data showed
that 71 out of 256 genes overlapped with AID binding
sites (Figure 2f), although a chi-square test indicated that
there is no significant enrichment. We also generated a
retroviral inducible system for AID in a B cell line to test
188
71
4535
D
0
5
10
15
R
el
at
iv
e 
Ex
pr
es
si
on AID
%
 C
D
86
 p
os
iti
ve
 c
el
ls
0
15
30
45
0
15
30
45
0
5
10
15
0
15
30
45
0
15
30
45
0
5
10
15
0
15
30
45
0
15
30
45
CCL3L1
RBL LCL
*** p= 0.00020 *** p= 0.00021
*** p= 0.00092 
CD19
** p= 0.00377
** p= 0.00201 
RBL LCLRBL LCL
FCER2
RBL LCLRBL LCL
TSSTSS
*** p= 0.00002 
*** p=0.00061
BLNK
%
M
et
hy
la
tio
n
(A
rr
ay
)
%
M
et
hy
la
tio
n
(P
yr
os
eq
ue
nc
in
g)
RBL LCL
RBL LCL
TSS
A
24h LCL0h
EB
N
A
2
D
A
PI
M
erge
B
0
20
40
60
CCL3L1
0
2
4
6
CD19
0
10
20
30
BLNK
%
M
et
hy
la
tio
n
(P
yr
os
eq
ue
nc
in
g)
C
E
0
25
50
75
FCER2
TSS
*** p= 0.00044 
G
0.0
0.4
0.8
1.2
0h 24h 72h 1w
Activated
EBV
BLNK
M
et
hy
la
tio
n
Le
ve
ls
0.0
0.4
0.8
1.2
0h 24h 72h 1w
CD19
Activated
EBV
0.0
0.4
0.8
1.2
0h 24h 72h 1w
FCER2
Activated
EBV
F
%
H
id
ro
xy
m
et
hy
la
tio
n
(r
el
at
iv
e 
to
 in
pu
t)
0
25
50
75
100
5hmC
No antibody
BLNK CCR7 CD19 FCER2 TRAF1
RBL LCL
AID targets
Hypomethylated
genes
RAJI RBL LCL
?-ACTIN
AID
0
30
60
90
120
0h 24h 72h 1w
Activated
EBV
100
0
25
50
75
%
B
rd
U
po
si
tiv
e 
ce
lls Activated
EBV
0h 24h 72h 1w
Figure 2 A comparison of the DNA methylation levels of selected genes between RBLs and resulting LCLs. (a) Bisulfite pyrosequencing
was performed for the genes selected from experiments with methylation arrays. The distribution of CpG sites (vertical black line), the
transcription start site (TSS; arrow) and the exact CpGs analyzed by the array (horizontal light grey bar) and pyrosequencing (horizontal dark grey
bar) are indicated above each gene. Average data from six samples is represented. (b) EBNA2 and DAPI staining of B lymphocytes at 0 and 24
hours after infection with EBV derived from 293 cells carrying a recombinant B95.8 EBV genome, and LCLs, in which high levels of infection were
achieved. (c) Pyrosequencing data showing the methylation changes at selected genes at different times. (d) Analysis of the 5-
hydroxymethylcytosine content/changes at CpG sites undergoing hypomethylation in selected genes. As a positive control, in vitro
hydroxymethylated DNA was used. (e) Changes in expression of activation-induced deaminase (AID) during RBL conversion to LCLs at the mRNA
and protein levels. For protein analysis, the Burkitt’s lymphoma cell line RAJI was used as a positive control for AID expression. (f) Overlap
between AID target genes and hypomethylated genes. (g) Comparison between B cells activated with IL4 and CD40L and infected with EBV.
The top panel shows the proportion of activated cells (left; determined by fluorescence-activated cell sorting (FACS) analysis with CD86) and
proportion of dividing cells (right; determined with bromodeoxyuridine (BrdU)). Bottom, bisulfite pyrosequencing analysis of selected CpGs in
association with EBV infection and with B cell activation by IL4 and CD40L. W, week.
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whether forced expression of this factor could lead to
hypomethylation in the aforementioned genes. Bisulfite
pyrosequencing of the same CpG sites of the previously
validated genes before and after expression of AID
showed no differences in methylation (not shown).
Given that EBV-mediated transformation and B cell acti-
vation share common pathways [25], we also performed
bisulfite pyrosequencing of these genes in B cells acti-
vated/stimulated with IL4 and CD40L to test the EBV-
associated specificity of the observed DNA demethylation
changes. Under our conditions we achieved similar levels
of both cell activation, measured by cytometry analysis of
CD86 surface marker, and proliferation, measured by bro-
modeoxyuridine (BrdU) incorporation (Figure 2g, top) in
both types of stimulation of B cells. However, no changes
in the DNA methylation levels of these genes were
observed during CD40L/IL4-stimulation of B cells (see
examples in Figure 2g, bottom) even after 1 week, suggest-
ing that methylation changes associated with EBV-
mediated transformation to LCLs are independent of
B cell activation.
Hypomethylated genes are enriched for binding of NF-B
and other lymphocyte-specific transcription factors
Our analysis of the dynamics of DNA demethylation sug-
gests that this process occurs in a replication-associated
manner, since changes only occurred once cell divisions
had started and did not involve changes in 5hmC or the
action of AID. In this context, hypomethylation could
potentially associate with genomic sites that are less effi-
cient in maintaining methylation during DNA replica-
tion, perhaps in regions that are associated with active
transcription in the context of B cell function.
Previous studies have shown that EBV transcription fac-
tor EBNA2 enhances and exploits the RBL transcription
program by binding to a variety of B cell transcription fac-
tor sites [4]. We wondered whether hypomethylation is
taking place at genomic sites bound by specific transcrip-
tion factors, perhaps associated with active transcription in
B cells. To address this, we investigated the possible
enrichment of transcription factor motifs from the
TRANSFAC database in a region of 500 bp around the
CpG sites in which hypomethylation had been detected in
our study. Significant enrichment of a small set of tran-
scription factors was observed. Remarkably, significant
enrichment of the binding motifs of two subunits of the
NF-B complex, specifically c-REL (9.3%, P-value = 2.0 ×
10-5) and p65/RELA (6.3%, P-value = 3.1 × 10-3) (Figure
3a) was observed. NF-B is known to be involved in the
survival of LCLs and latency III-regulated cell gene expres-
sion [26]. We also found enrichment of additional hema-
topoietic transcription factor binding motifs in this 500-bp
window around hypomethylated CpG sites, such as
GATA3, STAT1 and the MEF2 family (Figure 3a).
To evaluate the extent to which hypomethylated genes
correlate with NF-B occupancy, we used our methylation
data and ChIP-seq data for NF-B p65. Enriched NF-B
p65 peaks from a ChIP-seq study in lymphoblastoid cells
[27] were annotated to the nearest Ensembl gene build
(version 54) [28] using the Bioconductor package ChIP-
peakAnno [29]. All the targets from all four replicates
were uniquely combined. Overlap of hypomethylated
genes and NF-B p65 targets were represented in a Venn
diagram and the significance of overlap was determined by
a standard chi-square test, written in the syntax of the R
statistical program (Figure 3b).
We found that among the entire set of unique direct
NF-B p65 targets, 131 genes were shared with our list of
256 hypomethylated genes, that is, 51% of our hypomethy-
lated genes were directly associated with the NF-B p65
subunit (Figure 3b). Examples of the detailed binding of
NF-B p65 to these hypomethylated regions are shown in
Figure 3c. Additional ChIP-seq data for other transcription
factors were also used to investigate the overlap with
hypomethylated genes. Specifically, we used ChIP-seq data
from EBF1, IRF4, MEF2A, MEF2C, PAX5 and PU1
obtained from GM12878 cells (LCLs) from the ENCODE
project (Figure 3D). Remarkably, significant enrichment
was obtained for the binding of EBF1, IRF4 and MEF2C
(P-value < 0.05). EBF1 is a transcription factor that is criti-
cal for both B lymphopoiesis and B cell function [30].
IRF4 is as a crucial transcription factor in the generation
of functionally competent plasma B cells [31]. Finally,
transcription factor Mef2c is required for B cell prolifera-
tion and survival after antigen receptor stimulation [32].
chipseq
Our results suggested an association between genes that
are regulated by B cell-specific transcription factors, parti-
cularly some associated with B cell activation and prolif-
eration, and those that become hypomethylated. It is
possible that during transformation of B cells to prolifera-
tive lymphoblasts, cells are less efficient in maintaining
DNA methylation at actively transcribed sites, perhaps due
to a lower presence of DNA methyltransferases (DNMTs),
which are preferably bound to heterochromatic regions
[33,34]. One could argue that in quiescent B cells there is
a tendency for inactive genes to become methylated, and
when the cells are activated to grow and proliferate, genes
that become active lose methylation. This possibility was
partially discarded by analyzing the methylation levels in
CD40L/IL4-activated B cells (Figure 2g). Also, the analysis
of bone marrow CD19+ cells, where a high proportion of
B cells are proliferating [35], showed no methylation dif-
ferences with respect to peripheral blood CD19+ cells,
which are quiescent (Additional file 3). It could also be
possible that the finding of lower methylation levels in
proliferating B cells was due to the specific infection by
EBV of a B cell subpopulation with lower levels of
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methylation. To address that, we pyrosequenced several
genes in different B cell subpopulations present in periph-
eral blood, including naïve B cells, as well as unswitched
and switched memory B cells. No differences in methyla-
tion were observed with respect to total CD19+ cells from
peripheral blood or RBLs and they all displayed higher
methylation than LCLs (Additional file 3).
Several key genes are overexpressed is association with
hypomethylation during EBV-mediated transformation to
LCLs
Our findings suggest that many of the genes undergoing
hypomethylation are actively transcribed in B cells, and
therefore loss of methylation may not directly affect their
expression levels. However, it is important to determine
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whether hypomethylation is also associated with overex-
pression of genes that may confer an advantage to prolif-
erating B lymphoblasts.
To address this matter, we performed quantitative
PCR of the selected genes in the set of six paired RBL
and LCL samples (Figure 4a). Loss of methylation was
in some cases associated with an increase in gene
expression. This happens for instance for all bona fide
EBV-induced genes (EBI), like EBI1, EBI2 and EBI3 (Fig-
ure 4a). Individual analysis also showed increase in
mRNA levels for other genes, although in other cases
this correlation with hypomethylation did not occur,
and no changes or even a decrease in expression was
observed, although the fold change was relatively low
(see central and bottom panels in Figure 4a). This is not
surprising, given that the DNA methylation levels of
some of the genes undergoing hypomethylation in this
process were already relatively low in resting B cells. As
mentioned above, many of these hypomethylated genes
are key factors in B cell function (CD19, CD79a, BLNK,
and so on) and they are expected to be highly expressed
in resting B cells. To test whether RNA polymerase II
(Pol II) is associated with these genes we overlapped our
data with the ChIP-seq data and found that at least 111
of them were Pol II-bound genes (Figure 3b). Examples
of the detailed binding of Pol II to these hypomethylated
regions are shown in Figure 3c.
We tested whether our 256 hypomethylated genes
were generally highly expressed in B cells relative to
other cell types. Thus, we compared normalized Affyme-
trix mRNA expression data of 73 normal human tissues
[36]. Comparison of expression of the 256 hypomethy-
lated genes indicated that around 28% of them were
more highly expressed in B cells than the average
expression level of the 73 other tissue types (Figure 4b),
reinforcing our findings on the relevance of the B cell
context in the genes that undergo hypomethylation.
For a general comparison in the context of transfor-
mation of RBLs to LCLs, we compared the expression
profiles of the 256 genes hypomethylated in B and LCLs
(available at the Gene Expression Omnibus (GEO) data-
base under series accession number GSE26212) [16].
This revealed that around 41% of the genes displayed
high levels of expression in RBLs (Figure 4c). However,
around 59% of the remaining genes accomplished signif-
icant increase in gene expression (Figure 4b; Additional
file 4), correlating with the over two-fold reduction in
DNA methylation. Remarkably, the list of genes that
become hypomethylated and are overexpressed includes
several key genes in RBL to LCL conversion (Additional
file 4). For instance, EBI3 undergoes an approximately
five-fold change in methylation and becomes overex-
pressed. This gene is a subunit of the heterodimeric
cytokine IL27, known to be regulated through NF-B
activation [37] and to induce B cell proliferation, which
is stronger in naïve than in memory B cells [38].
Another example is LTA, or lymphotoxin alpha, a mem-
ber of the tumor necrosis factor family, and an auto-
crine growth factor induced upon binding of NF-B
[39]. Other examples in our list include genes like
SLAM1 and SLAMF7, two members of the ‘signaling
lymphocyte activation molecule’ (SLAM) family, also
implicated in B cell proliferation [40].
Pharmacologically induced DNA demethylation enhances
proliferation during RBL to LCL transformation
Our analysis revealed that a high proportion of the
genes that undergo hypomethylation during RBL to LCL
transformation become overexpressed and that several
of them are important for the transformation on con-
tinuous proliferating B lymphoblasts. To determine
whether hypomethylation has any effect on the effi-
ciency of transformation, we investigated whether phar-
macologically induced hypomethylation influences RBL
to LCL transformation. We tested the proliferation rate
in RBLs infected with EBV and incubated in the pre-
sence of increasing concentrations with the demethylat-
ing agent 5-azadeoxycytidine (azadC) at concentrations
between 50 pM and 50 μM. MTT assays showed that
mock-treated cells started to proliferate around day 6
after infection with EBV (Figure 5a). Cell viability and
proliferation rate decreased at very high doses of azadC,
consistent with the toxicity properties of azadC at high
doses, which we tested on cultured LCLs (Figure 5a).
However, at low azadC concentrations (50 pM, 500 pM
and 5 nM), where viability of cells is comparable to that
of control cells (Figure 5a), a significant increase in cell
proliferation was observed after day 8 (Figure 5b). This
increase in proliferation in the presence of azadC was
not observed when established LCLs were used as a
control in proliferation experiments in the presence of
azadC, suggesting that the effect of azadC is associated
with the transformation of RBLs to proliferating B cells.
Bisulfite genomic analysis of several of the target genes
confirmed the loss of methylation at the studied CpG
sites upon treatment with 5azadC at low concentrations
(Figure 5c). In fact, we observed that azadC-treated cells
had lower levels of methylation than control cells at day
10 (Figure 5c). Analysis of viral promoters showed that
these were unmethylated in both free viral particles and
in LCLs, ruling out the possibility that demethylation at
EBV promoters and overexpression of EBV-encoded
genes are responsible for more efficient transformation
of RBLs to LCLs.
Discussion
Our results provide evidence that EBV-mediated trans-
formation of RBLs to LCLs results in the demethylation
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of a cluster of around 250 genes. Conversely, no significant
hypermethylation is observed. Hypomethylation has been
described in various immune disease-related contexts,
including ICF (immunodeficiency, centromere instability
and facial anomalies) syndrome [41] and autoimmune dis-
eases [8]. In most cases, disease-associated hypomethy-
lation occurs at repetitive sequences, including Alu
elements [42]. However, in RBL to LCL transformation,
hypomethylation takes place near the transcription start
sites of around 250 genes, and no apparent hypomethyla-
tion occurs at the major type of repetitive elements. Lack
of hypomethylation in repetitive sequences is consistent
with the minimal changes in genomic stability associated
with EBV-associated lymphoproliferation.
Given that hypomethylation occurs in association with
the acquisition of proliferation, it is likely to be related to
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the decreased efficiency in DNA methylation maintenance
as cells start to divide. The lack of evidence for active
demethylation mechanisms during this process also sup-
ports the above possibility. The transition of a differen-
tiated resting cell to a proliferative status would require
the participation of DNMTs to maintain the DNA methy-
lation profiles throughout replication/division cycles. Var-
ious lines of evidence indicate that DNMTs are associated
with repetitive sequences [33,34] and that heterochromatic
regions act as a reservoir for DNMTs [33]. This would
explain why active regions, which are less rich in DNMTs,
lose methylation in the transformation from resting to
proliferative B cells, whereas in ICF syndrome, which is
characterized by mutations in DNMT3B, hypomethylation
takes place in heterochromatic regions, which act as reser-
voirs of DNMTs.
In fact, analysis of the regions associated with hypo-
methylation during RBL to LCL transformation shows
enrichment of highly expressed genes and target sites of
transcription factors that are expressed in B cells or are
specifically activated during EBV infection, such as factors
in the NF-B pathway [26,43]. The modulation of the NF-
B signaling by EBV is not only important for viral infec-
tion, but also contributes to the development of malignant
neoplasia [43]. In addition, our results indicate that hypo-
methylated genes are regulated by B cell-specific factors
like EBF1, IRF4 and MEF2C, the last two of which are
implicated in B cell activation and proliferation processes.
We also observed that many of the genes that undergo
hypomethylation, like CD19, CD79a, BLNK, BLK and
LCK, are highly expressed in B cells. This suggests that
active regions are either more accessible to putative
demethylating machinery or are less efficient at maintain-
ing methylation as proliferation starts. Given the lack
of demethylation events before proliferation begins, and
that we were unable to detect links between any of the
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proposed mechanisms associated with active demethyla-
tion, we favor the occurrence of a replication-coupled
mechanism of demethylation, due to the inefficient main-
tenance of DNA methylation as replication is initiated.
Similar to studies of the EBNA2 binding sites [4] in which
EBV exploits intrinsic B cell transcription programs, hypo-
methylation takes place preferentially in genes that are
expressed. Comparison of the lists of significantly hypo-
methylated genes and the presence of transcription factor
binding motifs and occupancy reinforced this notion. Data
from different sources suggest that transcriptionally active
regions are devoid of DNMTs, making the maintenance of
DNA methylation less efficient. On the other hand, since
the main functional consequence of promoter hypomethy-
lation would potentially be an increase in transcription, it
is likely that demethylation contributes to overexpression
of some of these genes. In this sense, we have identified
several key genes that undergo both hypomethylation and
overexpression during the conversion of RBLs to LCLs.
These include genes like EBI3 [37,38], a subunit of the
cytokine IL27, LTA [39] and members of the SLAM family
[40] among others that are known to contribute to lym-
phocyte proliferation (Additional file 4).
In addition, demethylation of genes that already have
high expression levels in the first set of infected cells
might also lock its transcriptional status, and therefore
would reinforce the B cell phenotype, and might be key
to enable infection of more B cells. EBV initially infects
oropharynx epithelial cells, establishing a lytic replica-
tion that spreads to some B cells in nearby lymphoid tis-
sues. Those expand as EBV establishes a type III latency
growth-transforming infection of B cells that elicit a
strong T-cell-specific response. Maintaining a B cell
phenotype would favor recirculation and generalized
expansion to B cell areas in secondary lymphoid organs
where surviving B cells downregulate EBV antigen
expression and establish long-term silent latency [44].
The functional relevance of demethylation in this pro-
cess is highlighted by the observation that treatment of
RBLs with azadC at low sub-toxic concentrations enhances
RBL to LCL transformation. Since the EBV genome is vir-
tually unmethylated in free viral particles, demethylation at
EBV promoters and overexpression of EBV-encoded genes
can be ruled out as responsible for more efficient transfor-
mation of RBLs to LCLs. Our findings on the enhanced
cell proliferation concomitantly associated with the pre-
sence of low sub-toxic amounts of azadC suggests that
initial DNA methylation changes may cooperate in the
efficiency of this process.
Although type III latency lymphoblastoid cells do not
necessarily correspond to initial steps of lymphomagenesis,
they both share enhanced proliferation [45]. It is likely that
hypomethylation occurs in early steps towards to lympho-
magenesis, when enhanced proliferation starts. In other
hematological neoplasias, like in acute myeoloid leukemia,
DNMT3A mutations are highly recurrent [46], and it has
been proposed that these mutations in an enzyme respon-
sible for the establishment of DNA methylation are an
early event of clonal evolution [47]. In B-cell chronic lym-
phocytic leukemia, increased levels of TCL1 result in inhi-
bition of DNA methylation [48]. Inhibition of methylation
is proposed to be a common oncogenic mechanism in leu-
kemogenesis [48]. These findings highlight the relevance
of our study as a potential early mechanism in this group
of tumors.
Conclusions
Our study of DNA methylation changes in EBV-mediated
transformation of RBLs to LCLs reveals that only promoter
hypomethylation occurs during this process. Neither signif-
icant hypermethylation nor methylation changes at repeti-
tive elements are observed. Hypomethylation takes place
only when proliferation has started, and the analysis of
putative elements of the active demethylation machinery
does not indicate their implication during this process.
Most genes undergoing hypomethylation are active and
display the presence of NF-B p65 and other B-cell-specific
transcription factors. Since DNMTs tend to associate with
heterochromatic regions, it is likely that maintenance of
DNA methylation is less efficient in transcriptionally active
regions as cells start to proliferate triggered by EBV; how-
ever, this process does not occur during CD40L/IL4-stimu-
lation of B cells where no changes are observed. Our
results show that hypomethylation is associated with
further upregulation of gene expression of many of these
genes. Also, pharmacologically induced demethylation
increases B cell transformation efficiency and proliferation.
Collectively, our data indicate that the B cell transcription
machinery is associated with the subset of genes that
undergo hypomethylation. The finding that relevant genes
in EBV-mediated transformation of B cells are further
upregulated indicates a key role of this mechanism. Hypo-
methylation has been proposed to play a role in early stages
of hematological malignancies, including other B cell
malignancies. Our data reinforce the notion of the role of
hypomethylation in early lymphomagenesis and shed light
on underlying mechanisms.
Materials and methods
Ethics statement
Human samples (blood) used in this study come from
anonymous blood donors and were obtained from the
Catalan blood donation center (Banc de Sang i Teixits).
Since the samples are anonymous, no informed consent
is therefore required. The protocol used to transform
with EBV B cells obtained from these anonymous donors
was approved by the Committee of Biosecurity of IDI-
BELL (CBS) on 5 May 2011 and the Ethics Committee of
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the University Hospital of Bellvitge (CEIC) on 28 May
2011.
Subjects and sample preparation
Buffy-coats from anonymous blood donors were obtained
from the Catalan blood donation center (Banc de Sang i
Teixits). Viable peripheral blood mononuclear cells were
isolated using LymphoprepTM density gradient centrifu-
gation. Resting B cells were isolated by positive selection
using CD19 MicroBeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany), or by depletion using a B Cell Isolation
Kit (Miltenyi Biotec). Isolated B cells were immortalized
with the supernatant of the EBV producer cell line B95.8
for the methylation studies and with the 2089 EBV made
from 293 cells carrying a recombinant B95.8 EBV genome
[20] for expression analysis.
DNA methylation profiling using universal bead arrays
Infinium Methylation Assay (Illumina, Inc., San Diego,
CA, USA) was used to analyze DNA methylation. The
HumanMethylation27 panel allows researchers to interro-
gate 27,578 highly informative CpG sites per sample at
single-nucleotide resolution. This panel targets CpG sites
located within the proximal promoter regions of transcrip-
tion start sites of 14,475 consensus coding sequencing
(CCDS) in the NCBI Database (Genome Build 36). In
addition, 254 assays cover 110 microRNA promoters. On
average, two assays were selected per CCDS gene and
from 3 to 20 CpG sites for > 200 cancer-related and
imprinted genes. Bisulfite conversion of DNA samples was
done using the EZ DNA methylation kit (Zymo Research,
Orange, CA, USA). After bisulfite treatment, the remain-
ing assay steps were identical to those of the Infimium
Methylation Assay, using reagents and conditions supplied
and recommended by Illumina. Two technical replicates
of each bisulfite-converted sample were run. The results
were all in close agreement and were averaged for subse-
quent analysis. The array hybridization was conducted
under a temperature gradient program, and arrays were
imaged using a BeadArray Reader (Illumina Inc.). The
image processing and intensity data extraction software
and procedures were those described by Bibikova and col-
leagues [49]. Each methylation data point was represented
as a combination of the Cy3 and Cy5 fluorescent intensi-
ties from the M (methylated) and U (unmethylated) alleles.
Background intensity computed from a set of negative
controls was subtracted from each data point.
Detection of differentially methylated genes from the
methylation array and functional analysis
A t-test was carried out to identify probes differentially
methylated between primary B cells relative to their
counterparts obtained in the LCL. P-values were
corrected for multiple testing using the method pro-
posed by Benjamini and Hochberg [50] to control the
FDR. Genes showing a FDR adjusted P-value < 0.05 and
a minimum mean methylation FC of two were consid-
ered to be differentially methylated. Functional annota-
tion of hypomethylated genes was based on GO
(Consortium, 2000), as extracted from EnsEMBL [28]
and the KEGG pathway database [51]. Accordingly, all
genes were classified into three ontologies, based on
their involvement in biological processes, molecular
functions and cellular components. We took only the
GO/pathway categories that had at least ten annotated
genes. We used GiTools for enrichment analysis and
heatmap generation [52]. Resulting P-values were
adjusted for multiple testing using Benjamini and Hoch-
berg’s FDR method [50]. An FDR cutoff of 0.25 was
used for selection of enriched terms. The relationships
between the DNA methylation data (from standard
bisulfite sequencing and/or quantitative bisulfite pyrose-
quencing) and the age and sex of the individuals were
evaluated by the Pearson chi-square test.
Analysis of gene promoter methylation: bisulfite
sequencing and pyrosequencing
CpG island DNA methylation status was determined by
sequencing bisulfite-modified genomic DNA. Bisulfite
modification of genomic DNA was carried out as described
by Herman et al. [53]. To validate the DNA methylation
data obtained by the Infinium methylation assay, bisulfite
pyrosequencing was performed according to standard pro-
tocols and evaluated with the Pyro Q-CpG 1.0.9 program
(Biotage, Uppsala, Sweden). Primer sequences, product
lengths and annealing temperatures used in the bisulfite
sequencing and bisulfite pyrosequencing PCR reactions are
shown in Additional file 5. Raw data for bisulfite sequen-
cing of all samples is presented in Additional file 6.
Amplification of unmethylated Alus (AUMA)
DNA digestion with SmaI enzyme and ligation to the lin-
ker were performed as described elsewhere [18]. The pro-
duct was purified using the GFX Kit (Amersham
Biosciences, Uppsala Sweden) and eluted in 250 μl of ster-
ile water. A chimeric primer comprising the complemen-
tary linker sequence (ATTCGCAAAGCTCTGA), the cut
SmaI site (GGG) and three additional nucleotides homolo-
gous to the Alu consensus sequence were used to enrich
for Alu sequences: AUMA-TTC (ATTCGCAAAGCTC
TGAGGGTTC). Single primers were used for each PCR
reaction. Products were resolved on denaturing sequen-
cing gels. Bands were visualized by silver staining the gels.
Faint bands with inconsistent display due to small varia-
tions in gel electrophoresis resolution were not considered.
Band reproducibility was assessed with the analysis of
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PCR duplicates. AUMA fingerprints were visually checked
for methylation differences between bands in different
samples. Based on these premises, a given band was scored
according to three possible behaviors: hypomethylation
(increased intensity), hypermethylation (decreased inten-
sity) and no change (no substantial difference between
samples). Only those bands showing clear changes in their
fingerprint intensities were considered to represent methy-
lation changes.
Quantitative RT-PCR expression analyses
We reverse-transcribed total RNA extracted with TRIzol
(Invitrogen), using a Transcriptor First Strand cDNA Synth-
esis Kit from Roche Diagnostics (Indianapolis, Indiana,
USA). Quantitative real-time PCR analysis was performed
in a PCR Real Time LightCycler 480 (Roche) with Sybr
green. Primer sequences are shown in Additional file 5.
Analysis of transcription factor binding
Possible enrichment of transcription factor motif in the
500- to 1,000-bp region around the center of the hypo-
methylated probes and all other probes were predicted
with the STORM algorithm [54], assuming P-value cutoffs
of 0.00002 and 0.00001, respectively, using position fre-
quency matrices (PFMs) from the TRANSFAC database
(Professional version, release 2009.4) [55]. Enrichment
analysis of predicted transcription factors in the probes of
significant hypomethylated probes (n = 421) were con-
ducted using GiTools [52]. We calculated a two-tailed
P-value, and a finally adjusted FDR P-value (with 0.25 cut-
off) was considered in establishing statistical significance.
We downloaded EBF1, IRF4, MEF2A, MEF2C, PAX5
and PU1 binding ChIPseq data for the GM12878 cell line
from the ENCODE project [56]. Original hg19 genomic
co-ordinates were converted to hg18 using the USCS ‘lift-
over’ tool. RUNX ChIPseq target data were obtained
from the study of Hollenhorst and colleagues [57] (Jurkat
cell line, GEO Database ID: GSE17954). RBPJ and
EBNA2 taken from a 2011 study of Zhao et al. [4] (GEO
database ID: GSE29498). In this case, mapped data were
analyzed using the MACS (version 1.3.7.1) [58] pipeline
to call peaks. In all cases, peaks were annotated to the
nearest EnsEMBL [28] gene (version 54) using the Bio-
conductor package ChIPpeakAnno [29].
Expression analysis of hypomethylated genes in various
tissue types
Expression data on RBL and LCL from the study of Calis-
kan and colleagues [16] (GEO accession GSE26210) were
used to determine the relative expression of hypomethy-
lated genes in these two cell types. Probes were annotated
to Refseq genes and when more than one probe was pre-
sent for the same gene, they were averaged. Also, all
replicates on same sample were averaged. Expression
data were normalized by median-centering the expres-
sion value of each gene across all the samples and divid-
ing the value by the standard deviation. These
normalized values were delineated in a color-coded heat-
map using GiTools [52].
Normalized mRNA expression of data of 73 normal
human tissues was downloaded from the BioGPS data-
base [36] and analyzed similarly.
Cell proliferation and viability assays
In cell proliferation analysis, different dilutions of cells
were plated and cultured at 37°C in 5% CO2/95% O2 for
20 days. AzadC (Sigma, St. Louis, MO, USA) was used in
serial dilutions between 50 pM and 50 μM and refreshed
on day 4 of treatment. Every 2 days, cells were fixed and
stained with MTT and incubated for 4 hours at 37°C. The
reaction was stopped with 50% N,N-dimethylformamide,
30% SDS, 2.5% glacial acetic acid and 2.5% acid chloride
1 N, and incubated overnight at 37°C in 5% CO2/95% O2.
Cell quantities were determined by measuring the optical
density at 560 nm. All assays were performed in triplicate.
Cell viability was determined by the incorporation of pro-
pidium iodide in dead cells measured by flow cytometry.
CD40L activation of B cells
B cells were cultured at 1.5 × 106 cells/ml and activated
with 50 ng/ml of M.CD40L (Enzo Life Sciences, Lausen,
Switzerland) and 50 ng/ml of IL4 (Gentaur, Kampenhout,
Belgium). The percentage of activated RBLs was deter-
mined by CD86 expression measured by flow cytometry
and proliferating B cells were detected by measuring
BrdU incorporation.
Use of a B-cell-based inducible system to test AID activity
Jiyoye B cells with inducible expression of AID were gen-
erated using the Retro-X TM Tet-ON® Advanced Indu-
cible Expression System (Clontech, Saint-Germain-en-
Laye, France). This system works through the sequential
infection of the RetroX-Tet-ON advanced vector and the
pRetroX-Tight-Pur vector. Carboxy-terminal hemaggluti-
nin (HA)-tagged human AID was cloned in the pRetroX-
Tight-Pur vector. The stable doubly infected cell line was
selected with Geneticin (1 mg/ml) and Puromycin (0.3
μg/ml). AID expression was induced by the addition of
doxycycline (500 ng/ml) for 24 hours. Nuclear export
was inhibited by the addition of leptomycin B (10 ng/ml)
for 2 hours.
Data access
Methylation array data for this publication have been
deposited in NCBI’s GEO and is accessible through
GEO series accession number GSE41957 [59].
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Additional material
Additional file 1: Hypomethylated genes in RBL to LCL
transformation for a FDR adjusted P-value < 0.05 and fold change
(FC) ≥ 2 from bead array analysis.
Additional file 2: Comparison of the methylation levels (in
percentage) for selected genes from the bead arrays and calculated
after bisulfite pyrosequencing.
Additional file 3: A comparison of the DNA methylation levels of
selected genes in different B cell types. Bisulfite pyrosequencing was
performed for the genes selected from experiments with methylation
arrays. The analysis includes bone marrow (BM) CD19+ cells, naïve B cells,
unswitched (US) memory B cells and switched (S) memory cells. Also
peripheral blood resting B cells (RBLs) and corresponding lymphoblastoid
B cells (LCLs) are included.
Additional file 4: Expression changes between those undergoing
hypomethylation during the conversion between resting B cells
and lymphoblastoid cells.
Additional file 5: Primer sequences.
Additional file 6: Individual raw data corresponding to bisulfite
pyrosequencing presented in Figure 2.
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